|
🐜
|
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
30 auth.
A. Chan,
S. Delaloge,
F. Holmes,
B. Moy,
H. Iwata,
V. Harvey,
N. Robert,
T. Silovski,
E. Gokmen,
G. von Minckwitz,
B. Ejlertsen,
S. Chia,
J. Mansi,
C. Barrios,
M. Gnant,
...
M. Buyse,
I. Gore,
John A. Smith,
G. Harker,
N. Masuda,
K. Petráková,
Á. G. Zotano,
N. Iannotti,
G. Rodriguez,
P. Tassone,
A. Wong,
R. Bryce,
Y. Ye,
B. Yao,
Miguel Martín
|
8 |
2016 |
8
🐜
|
|
🐜
|
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
34 auth.
Miguel Martín,
F. Holmes,
B. Ejlertsen,
S. Delaloge,
B. Moy,
H. Iwata,
G. von Minckwitz,
S. Chia,
J. Mansi,
C. Barrios,
M. Gnant,
Z. Tomašević,
N. Denduluri,
R. Šeparović,
E. Gokmen,
...
A. Bashford,
M. Ruíz Borrego,
Sung-Bae Kim,
E. Jakobsen,
A. Cicėnienė,
Kenichi Inoue,
F. Overkamp,
J. Heijns,
A. Armstrong,
J. Link,
A. Joy,
R. Bryce,
A. Wong,
S. Moran,
B. Yao,
Feng Xu,
A. Auerbach,
M. Buyse,
A. Chan
|
8 |
2017 |
8
🐜
|
|
🐜
|
Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial.
18 auth.
A. Awada,
R. Colomer,
Kenichi Inoue,
I. Bondarenko,
R. Badwe,
G. Demetriou,
Soo-Chin Lee,
A. Mehta,
Sung-Bae Kim,
T. Bachelot,
...
C. Goswami,
S. Deo,
R. Bose,
A. Wong,
Feng Xu,
B. Yao,
R. Bryce,
L. Carey
|
8 |
2016 |
8
🐜
|
|
🐜
|
Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial.
31 auth.
A. Chan,
B. Moy,
J. Mansi,
B. Ejlertsen,
F. Holmes,
S. Chia,
H. Iwata,
M. Gnant,
S. Loibl,
C. Barrios,
I. Somalı,
S. Smichkoska,
N. Martínez,
M. Alonso,
J. Link,
...
I. Mayer,
S. Cold,
S. M. Murillo,
F. Senecal,
Kenichi Inoue,
M. Ruíz-Borrego,
R. Hui,
N. Denduluri,
D. Patt,
H. Rugo,
S. Johnston,
R. Bryce,
Bo Zhang,
Feng Xu,
A. Wong,
Miguel Martín
|
7 |
2020 |
7
🐜
|
|
🐜
|
Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial.
19 auth.
C. Saura,
Mafalda Oliveira,
Yin-Hsun Feng,
M. Dai,
S. Hurvitz,
Sung-Bae Kim,
B. Moy,
S. Delaloge,
W. Gradishar,
N. Masuda,
...
M. Pálácova,
M. Trudeau,
J. Mattson,
Y. Yap,
R. Bryce,
B. Yao,
J. Bebchuk,
K. Keyvanjah,
A. Brufsky
|
6 |
2019 |
6
🐜
|
|
🐜
|
Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer.
47 auth.
L. Smyth,
S. Piha-Paul,
H. Won,
A. Schram,
C. Saura,
S. Loi,
Janice M. Lu,
G. Shapiro,
D. Juric,
I. Mayer,
C. Arteaga,
M. I. de la Fuente,
A. Brufksy,
I. Spanggaard,
M. Mau-Sørensen,
...
M. Arnedos,
V. Moreno,
V. Boni,
J. Sohn,
L. Schwartzberg,
X. Gonzalez-Farré,
A. Cervantes,
F. Bidard,
A. Gorelick,
R. Lanman,
R. Nagy,
G. Ulaner,
S. Chandarlapaty,
K. Jhaveri,
Elena I. Gavrila,
Catherine Zimel,
S. D. Selcuklu,
Myra Melcer,
A. Samoila,
Yanyan Cai,
M. Scaltriti,
G. Mann,
Feng Xu,
L. Eli,
M. Dujka,
A. Lalani,
R. Bryce,
J. Baselga,
B. Taylor,
D. Solit,
F. Meric-Bernstam,
D. Hyman
|
6 |
2019 |
6
🐜
|
|
🐜
|
Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: diarrheal toxicity in the CONTROL trial.
53 auth.
C. Barcenas,
S. Hurvitz,
J. A. Palma,
R. Bose,
A. J. Chien,
N. Iannotti,
G. Marx,
A. Brufsky,
A. Litvak,
E. Ibrahim,
R. Alvarez,
M. Ruíz-Borrego,
N. Chan,
Y. Manalo,
A. Kellum,
...
M. Trudeau,
M. Thirlwell,
J. G. Saenz,
D. Hunt,
R. Bryce,
L. Mcculloch,
H. Rugo,
D. Tripathy,
A. Chan,
L. Carcas,
A. Castrellon,
D. Chan,
K. Cheong,
B. Choi,
M. Coleman,
A. Conlin,
R. Dichmann,
D. Ellison,
N. Erickson,
I. Gore,
Vincent Hansen,
D. Huang,
D. Hufnagel,
F. Kass,
S. D. Kendall,
M. Kozloff,
W. Lawler,
K. D. Nahum,
B. Pistilli,
E. Reyes,
J. Seeger,
R. Somer,
E. Chiu,
G. Thomas,
K. Tkaczuk,
I. Vaziri,
J. Wade,
M. Wilkinson
|
6 |
2020 |
6
🐜
|
|
🐜
|
The characterization, management, and future considerations for ErbB-family TKI-associated diarrhea
7 auth.
H. Rugo,
J. D. Di Palma,
D. Tripathy,
R. Bryce,
S. Moran,
E. Olek,
...
L. Bosserman
|
5 |
2019 |
5
🐜
|
|
🐜
|
Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial
23 auth.
S. Hurvitz,
C. Saura,
Mafalda Oliveira,
M. Trudeau,
B. Moy,
S. Delaloge,
W. Gradishar,
Sung-Bae Kim,
B. Haley,
L. Ryvo,
...
M. Dai,
V. Milovanov,
J. Alarcón,
S. Kalmadi,
E. Cronemberger,
C. Souza,
L. Landeiro,
R. Bose,
J. Bebchuk,
F. Kabbinavar,
R. Bryce,
K. Keyvanjah,
A. Brufsky
|
5 |
2021 |
5
🐜
|
|
🐬
|
Design and rationale of FOCUS (PX-171-011): A randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM)
R. Hájek,
R. Bryce,
S. Ro,
B. Klencke,
H. Ludwig
|
5 |
2012 |
5
🐬
|
